PDE5 was also found differentially expressed in breast cancer subtypes, with higher expression levels in the more aggressive HER2-enriched and triple-negative subtypes and lower levels in the estrogen receptor (ER)-positive Luminal B- and the Luminal A subtypes (123). This evidence concerns the gene ESR1 and breast carcinoma.